Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) Q2 2020 Earnings Conference Call - Final Transcript
Aug 12, 2020 • 08:30 am ET
Hello and welcome to Aerpio Pharmaceuticals Second Quarter 2020 Earnings Conference Call. [Operator Instructions]
It is now my pleasure to turn the call over to Gina Marek, Vice President of Finance. Please go ahead.
Good morning and thank you for joining us for Aerpio's second quarter 2020 earnings call. Joining me on the call today from Aerpio is Joseph Gardner, President and Founder.
This morning Aerpio released financial results for the second quarter ended June 30, 2020. If you have not received the news release or if you would like to be added to the company's distribution list, you can do so on the Investor Relations page on our website at aerpio.com.
I'd also like to remind you that the remarks made on the call today include forward-looking statements about Aerpio. Such statements may include, but are not limited to those related to Aerpio and its business and its product candidates including razuprotafib, also called AKB-9778, ARP-1536 and the bispecific antibody asset; the clinical development plans therefore and therapeutic potential thereof.
Our plans and expectations with respect to razuprotafib and the development therefore and therapeutic potential thereof in addressing COVID-19 and the intended benefits from Aerpio's collaboration with Gossamer Bio, Inc. for GB004. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement.
A more complete description of these and other material risks can be found in Aerpio's reports filed from time to time with the SEC. Aerpio does not undertake any obligation to update publicly any forward-looking statements whether as a result of new information, future events or otherwise.
I will now turn the call over to our President and Founder, Joseph Gardner. Joseph?
Good morning. This is Joseph Gardner, President of Aerpio Pharmaceuticals. I'm very pleased to share an update on our 2020 progress with our investors.As announced previously, we started our Phase 2 trial of a topical ocular formulation of razuprotafib in glaucoma, for which we expect top line results by the end of year 2020 ahead of the earlier guidance we provided.
As announced on June 24, we have over 20 clinical sites actively screening patients for the trial with a target enrollment of 195. We now have 170 patients enrolled, including those in the 28-day washout period and those in the drug treatment period. Based on these results, we are well on our way to meet our target of 195 patients completing the 28-day drug treatment regimen.
Expect -- and we expect the trial to be fully enrolled by October. Our investigators have been extremely enthusiastic to return to their practices after the lifting of the COVID quarantine in large regions of the country. And they are very interested in working with an agent that has a novel mechanism of action that lowers the resistance to fluid outflow via Schlemm's canal, thereby lowering intraocular pressure which I will refer to as IOP.
Notably, this IOP lowering signal was seen in two